ABVC BioPharma (ABVC) Competitors

ABVC BioPharma (NASDAQ:ABVC) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Does the media favor ABVC or CTXR?

In the previous week, ABVC BioPharma had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for ABVC BioPharma and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.00 beat ABVC BioPharma's score of -0.22 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of ABVC or CTXR?

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by company insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has stronger valuation & earnings, ABVC or CTXR?

ABVC BioPharma has higher revenue and earnings than Citius Pharmaceuticals. ABVC BioPharma is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$509.79K	13.77	-$10.52M	-$0.86	-0.63
Citius Pharmaceuticals	N/A	N/A	-$39.14M	-$6.00	-0.54

Which has more volatility & risk, ABVC or CTXR?

ABVC BioPharma has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.

Does the MarketBeat Community prefer ABVC or CTXR?

Citius Pharmaceuticals received 211 more outperform votes than ABVC BioPharma when rated by MarketBeat users.

Company	Underperform	Outperform
ABVC BioPharma	N/A	N/A
Citius Pharmaceuticals	Outperform Votes 211 62.43%	Underperform Votes 127 37.57%

Do analysts rate ABVC or CTXR?

Citius Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 1,576.92%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Citius Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Is ABVC or CTXR more profitable?

Citius Pharmaceuticals has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. Citius Pharmaceuticals' return on equity of -48.42% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	-1,619.65%	-104.94%	-56.81%
Citius Pharmaceuticals	N/A	-48.42%	-39.24%

Summary

Citius Pharmaceuticals beats ABVC BioPharma on 13 of the 17 factors compared between the two stocks.